{
    "clinical_study": {
        "@rank": "56947", 
        "brief_summary": {
            "textblock": "The objective of the non-interventional study is to compare the quality of life, health care\n      resource use and costs between the use of a combination of oxycodone and naloxone (Targiniq)\n      versus oxycodone and laxatives for patients with severe pain, and to evaluate the\n      cost-effectiveness of treatment with Targiniq."
        }, 
        "brief_title": "Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pain", 
            "Opioid Induced Constipation"
        ], 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Male or non-pregnant female \u226518 years of age\n\n          -  Malignant or non-malignant opioid sensitive pain\n\n          -  Must sign an informed consent form (ICF)\n\n          -  Must have a stable daily dose of oxycodone prolonged release formulation titrated to\n             analgesic effect (as to be assessed by clinical experts)\n\n          -  Use of laxatives for concomitant opioid-induced constipation in an adequate dose and\n             length of time and without sufficient effect\n\n          -  BFI \u226530 and state a discomfort caused by the constipation at screening\n\n          -  Ability to answer the patient questionnaires and have an estimated overall life\n             expectancy of at least six (6) months\n\n        Exclusion criteria:\n\n          -  History of, or on-going, abuse of alcohol and/or drugs\n\n          -  Inability to read and understand written instructions, ICF or questionnaires\n\n          -  Constipation not related to opioid use\n\n          -  Unsuitable patient for other reason(s) in the opinion of the investigator\n\n          -  Inpatients, if admission and/or discharge is expected during study period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The patients have severe pain treated with opioids and will be enrolled at different\n        clinics in Sweden"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812733", 
            "org_study_id": "OXN9513"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Laxatives", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "\u00d6rebro", 
                    "country": "Sweden"
                }, 
                "name": "Rehabiliteringsmedicinska kliniken"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of Quality of Life, Resource Use and Costs Associated With Treatment of Severe Pain - a Comparison of a Combination of Oxycodone and Naloxone (Targiniq) Versus Oxycodone and Laxatives", 
        "overall_contact": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "/Margaret Wilson"
        }, 
        "overall_contact_backup": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "Jill Kiteley"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Two visits performed over 8 weeks", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812733"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mundipharma AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}